Overall, 255 (11%) received anthracyclines, 29 (1%) received HER2-targeted therapy, 52 (2%) received an intravenous VEGF inhibitor, 41 (2%) received myeloma therapy, and 157 (7%) received cardiotoxic RT. This evidence concerns the gene VEGFA and plasma cell myeloma.